BioSpace News Archive

The Muscular Dystrophy Association (MDA) today launched the nation’s largest St. Patrick’s fundraising program, the 38th annual MDA Shamrocks campaign.

TruMed® Systems, Inc., makers of the AccuVax Vaccine Management System, releases Patient Safety Checks feature for AccuVax ES.

BETHESDA, Md. , Feb. 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder’s Meeting will be held on April 18, 2020 , at 1:00 pm in Washington, DC . The Company encou

Feb. 18, 2020 14:00 UTC CHICAGO--( BUSINESS WIRE )-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference. Date: Tuesday, February 2

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, 2020

Lantheus Holdings, Inc. announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020, to discuss its financial and operating results for the fourth quarter and full year of 2019.

Arrevus announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ARV-1801 for the treatment of cystic fibrosis.

Kannalife, Inc. announced that China has issued the Company, Chinese Patent CN106456573B specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” which further bolsters the Company’s global patent portfolio of cannabidiol -like molecules.